type stringclasses 2
values | question stringlengths 13 210 | answer stringlengths 5 521 | golden_answers sequencelengths 1 22 | ideal_answer stringlengths 3 22.1k | documents sequencelengths 1 133 | snippets listlengths 0 126 | asq_challenge int64 3 13 | folder_name stringclasses 8
values | concepts sequencelengths 0 97 ⌀ | triples listlengths 0 4.35k ⌀ | id stringlengths 24 24 | data_source stringclasses 2
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
factoid | Abnormality in which vertebral region is important in the Bertolotti's syndrome? | ['lumbosacral'] | [
"lumbosacral",
"lumbosacral region",
"lumbosacral plexus",
"lumbosacral spine",
"lumbosacral junction"
] | Lumbosacral vertebral region is implicated in the Bertolotti's syndrome. Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can form a joint or fusion with the sacrum or ilium. Patients often complain of intractable sciatica that arises from... | [
"http://www.ncbi.nlm.nih.gov/pubmed/24156003",
"http://www.ncbi.nlm.nih.gov/pubmed/21511940",
"http://www.ncbi.nlm.nih.gov/pubmed/20624239",
"http://www.ncbi.nlm.nih.gov/pubmed/19830065",
"http://www.ncbi.nlm.nih.gov/pubmed/19646556",
"http://www.ncbi.nlm.nih.gov/pubmed/19547821",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24156003",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 155,
"text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae, is an important cause of low... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013131",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
"http://www.disease-ontology.org/api/metadata/DOID:225"
] | [
{
"o": "http://linkedlifedata.com/resource/pubmed/keyword/LUMBOSACRAL+REGION%2Fabnormalities",
"p": "http://linkedlifedata.com/resource/pubmed/keyword",
"s": "http://linkedlifedata.com/resource/pubmed/id/13767955"
},
{
"o": "http://linkedlifedata.com/resource/pubmed/keyword/LUMBOSACRAL+REGION%2F... | 5313058de3eabad02100000e | bioasq_factoid |
yesno | Can the Micro-C XL method achieve mononucleosome resolution? | ['yes'] | [
"yes"
] | ['Yes. Micro-C XL is an improved method for analysis of chromosome folding at mononucleosome resolution.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/27723753"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution"
},
... | 6 | BioASQ-training6b | null | null | 587dfde9ae05ffb474000001 | bioasq_yesno |
factoid | What is commotio cordis? | ['blunt thoracic impact causing sudden death'] | [
"blunt thoracic impact causing sudden death",
"blunt chest trauma leading to sudden death",
"blunt chest impact resulting in sudden death",
"blunt thoracic trauma causing sudden death",
"blunt force trauma to the chest leading to sudden death"
] | Commotio cordis is a term used to describe cases of blunt thoracic impact causing sudden death without structural damage of the heart | [
"http://www.ncbi.nlm.nih.gov/pubmed/22816548",
"http://www.ncbi.nlm.nih.gov/pubmed/14646469",
"http://www.ncbi.nlm.nih.gov/pubmed/11879111",
"http://www.ncbi.nlm.nih.gov/pubmed/10894918",
"http://www.ncbi.nlm.nih.gov/pubmed/10498299",
"http://www.ncbi.nlm.nih.gov/pubmed/9703576",
"http://www.ncbi.nlm.ni... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22816548",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 181,
"text": "Commotio cordis is a rare type of blunt cardiac injury in which low impact chest trauma causes sudden cardiac arre... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056104"
] | [] | 53035d7c2059c6d71c000085 | bioasq_factoid |
factoid | What is the incidence of Facioscapulohumeral Muscular Dystrophy? | ['1:8000 to 1:20000'] | [
"1:8000 to 1:20000",
"1:8000-1:20000",
"1:8000-20000",
"1:8000 to 20000",
"1:8000 - 1:20000"
] | ['Facioscapulohumeral Muscular Dystrophy has and incidence of 1:8000 to 1:20000.', 'The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) is approximately 1 in 8000 individuals.', 'The incidence of Facioscapulohumeral Muscular Dystrophy is approximately 1 in 8,000.', 'The incidence of Facioscapulohumeral Muscu... | [
"http://www.ncbi.nlm.nih.gov/pubmed/34315378",
"http://www.ncbi.nlm.nih.gov/pubmed/21496633"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34315378",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 127,
"text": "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:80... | 12 | BioASQ-training12b | null | null | 64425ce357b1c7a315000059 | bioasq_factoid |
factoid | Which disease was studied in the CADISS trial? | ['carotid and vertebral artery dissection'] | [
"carotid and vertebral artery dissection",
"CVA dissection",
"carotid artery dissection",
"vertebral artery dissection",
"cervical artery dissection",
"cervical artery dissection syndrome",
"carotid and vertebral artery injury"
] | ['CADISS was a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/28087823",
"http://www.ncbi.nlm.nih.gov/pubmed/18705933",
"http://www.ncbi.nlm.nih.gov/pubmed/22855862",
"http://www.ncbi.nlm.nih.gov/pubmed/22110554",
"http://www.ncbi.nlm.nih.gov/pubmed/19386884",
"http://www.ncbi.nlm.nih.gov/pubmed/30801621",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28087823",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 87,
"text": "Prognosis of carotid dissecting aneurysms: Results from CADISS and a systematic review."
},
{
"beginSection": "ab... | 11 | BioASQ-training11b | null | null | 5e4604d83f54159529000003 | bioasq_factoid |
yesno | Does an interferon (IFN) signature exist for SLE patients? | ['yes'] | [
"yes"
] | ['Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. An IFN-I score (positive or negative), as a measure of IFN-I activation, is assessed using the expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs).... | [
"http://www.ncbi.nlm.nih.gov/pubmed/29850618",
"http://www.ncbi.nlm.nih.gov/pubmed/21576205",
"http://www.ncbi.nlm.nih.gov/pubmed/29321042",
"http://www.ncbi.nlm.nih.gov/pubmed/28830352"
] | [
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
"endSection": "title",
"offsetInBeginSection": 69,
"offsetInEndSection": 167,
"text": "Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease."
},
{
"begin... | 11 | BioASQ-training11b | null | null | 5c7019557c78d6947100005f | bioasq_yesno |
yesno | Are variants in FHF2 (also known as FGF13) associated with encephalopathy? | ['yes'] | [
"yes"
] | ['Yes. FHF2 (also known as FGF13) variants are a cause of infantile-onset developmental and epileptic encephalopathy.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/33245860"
] | [
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33245860",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "Missense variants in the N-terminal domain of the A isoform of FHF2/FGF13 cause an X-linked developmental and epileptic ... | 11 | BioASQ-training11b | null | null | 61f9605f882a024a1000004f | bioasq_yesno |
yesno | Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients? | ['no'] | [
"no"
] | ['No, LY6K overexpression is associated with poor prognosis for patients with NSCLC.', 'No, overexpression of LY6K has been found to be associated with poor prognosis for non-small cell lung cancer patients.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/18089789"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18089789",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 570,
"text": "Gene expression profile analyses of non-small cell lung carcinomas (NSCLC) and esophageal squamous cell carcinomas... | 11 | BioASQ-training11b | null | null | 5e49c5336d0a277941000011 | bioasq_yesno |
yesno | Are there randomised controlled trials on sevoflurane? | ['yes'] | [
"yes"
] | ['Yes. There are < 10 studies reported, answering questions like : how to improve speed of recovery, relationship to dreaming and anesthetic experience, effect on cardiac troponin release, effect on myocardial injury, postoperative delirium, haemodynamics & emergence and recovery characteristics of total intravenous a... | [
"http://www.ncbi.nlm.nih.gov/pubmed/23452265",
"http://www.ncbi.nlm.nih.gov/pubmed/22577917",
"http://www.ncbi.nlm.nih.gov/pubmed/22103571",
"http://www.ncbi.nlm.nih.gov/pubmed/21733178",
"http://www.ncbi.nlm.nih.gov/pubmed/21675061",
"http://www.ncbi.nlm.nih.gov/pubmed/20683334",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "sections.0",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23452265",
"endSection": "sections.0",
"offsetInBeginSection": 459,
"offsetInEndSection": 641,
"text": "After Ethics Review Board approval, 44 ASA I-III patients undergoing elective gynaecological surgery were ra... | 5 | BioASQ-training5b | [
"http://www.biosemantics.org/jochem#4252326"
] | null | 515d9e5c298dcd4e5100000e | bioasq_yesno |
yesno | Has ivosidenib been FDA approved for use against acute myeloid leukemia? | ['yes'] | [
"yes"
] | ['The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/30093505"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia. "
}
] | 11 | BioASQ-training11b | null | null | 5c65495be842deac67000021 | bioasq_yesno |
yesno | Is ocrelizumab effective for primary progressive multiple sclerosis? | ['yes'] | [
"yes"
] | ['Yes, ocrelizumab is effective and approved for primary progressive multiple sclerosis.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/35583174",
"http://www.ncbi.nlm.nih.gov/pubmed/35590041",
"http://www.ncbi.nlm.nih.gov/pubmed/35192158"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35192158",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 232,
"text": "Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the ... | 12 | BioASQ-training12b | null | null | 6404199d201352f04a000019 | bioasq_yesno |
factoid | What does the gene symbol EREG stand for? | ['epiregulin'] | [
"epiregulin",
"EREG",
"epiregulin precursor",
"epiregulin protein",
"epiregulin isoform"
] | ['The gene symbol EREG stands for the gene epiregulin.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/34667080"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34667080",
"endSection": "abstract",
"offsetInBeginSection": 268,
"offsetInEndSection": 569,
"text": "We found that epidermal growth factor (EGF)-deficient cells exhibited lower basal ERK activity than the cells de... | 11 | BioASQ-training11b | null | null | 6237a5513a8413c6530000b0 | bioasq_factoid |
yesno | Do brown fat cells produce heat? | ['yes'] | [
"yes"
] | ['Yes, brown fat cells produce heat.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/23834768",
"http://www.ncbi.nlm.nih.gov/pubmed/26910308",
"http://www.ncbi.nlm.nih.gov/pubmed/22796012",
"http://www.ncbi.nlm.nih.gov/pubmed/21196229",
"http://www.ncbi.nlm.nih.gov/pubmed/23818608",
"http://www.ncbi.nlm.nih.gov/pubmed/6148836",
"http://www.ncbi.nlm.ni... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24567786",
"endSection": "abstract",
"offsetInBeginSection": 271,
"offsetInEndSection": 512,
"text": "WAT and BAT are both involved in energy balance. WAT is mainly involved in the storage and mobilization of energ... | 6 | BioASQ-training6b | [
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477",
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002001",
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052437",
"https://www.nlm.nih.gov/cgi/me... | [
{
"o": "Heat",
"p": "http://www.w3.org/2000/01/rdf-schema#label",
"s": "http://linkedlifedata.com/resource/umls/id/C0018837"
},
{
"o": "http://linkedlifedata.com/resource/umls/label/A0066521",
"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
"s": "http://linkedlifedata.com/resource/uml... | 58ca906a02b8c6095300002e | bioasq_yesno |
yesno | Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria? | ['yes'] | [
"yes"
] | ['Yes, OXLUMO (lumasiran) is approved for the treatment of primary hyperoxaluria type 1 (PH1) in adults and children aged 6 years and older.', 'Yes, OXLUMO (lumasiran) is used for the treatment of primary hyperoxaluria.', 'OXLUMO (lumasiran) for the treatment of primary hyperoxaluria', 'Lumasiran (Oxlumo™) is a subcuta... | [
"http://www.ncbi.nlm.nih.gov/pubmed/33789010",
"http://www.ncbi.nlm.nih.gov/pubmed/34154993",
"http://www.ncbi.nlm.nih.gov/pubmed/34022071",
"http://www.ncbi.nlm.nih.gov/pubmed/33985991",
"http://www.ncbi.nlm.nih.gov/pubmed/35237473",
"http://www.ncbi.nlm.nih.gov/pubmed/35747094",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33405070",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 268,
"text": "Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxya... | 12 | BioASQ-training12b | null | null | 64281a47690f196b5100004f | bioasq_yesno |
yesno | Is Mycobacterium avium less susceptible to antibiotics than Mycobacterium tuberculosis? | ['yes'] | [
"yes"
] | ['Mycobacterium avium causes disseminated infection in patients with acquired immune deficiency syndrome. M tuberculosis disease is preventable and curable and yet communicable, physicians should maintain a high degree of suspicion for tuberculosis in HIV-infected adults. In comparison, the goal of treating M avium com... | [
"http://www.ncbi.nlm.nih.gov/pubmed/21258569",
"http://www.ncbi.nlm.nih.gov/pubmed/19302308",
"http://www.ncbi.nlm.nih.gov/pubmed/16410940",
"http://www.ncbi.nlm.nih.gov/pubmed/15347635",
"http://www.ncbi.nlm.nih.gov/pubmed/12355367",
"http://www.ncbi.nlm.nih.gov/pubmed/10988097",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21258569",
"endSection": "abstract",
"offsetInBeginSection": 1447,
"offsetInEndSection": 1550,
"text": "The prevalence of MAC lung infection in two inner city hospitals was four times higher than that of TB."
},
... | 5 | BioASQ-training5b | [] | [] | 5710a650cf1c32585100002b | bioasq_yesno |
yesno | Is there a relationship between thyroid hormone altered metabolism and coronary artery disease? | ['yes'] | [
"yes"
] | The major part of the studies and metaanalysis data show that hypothyroidism, both primary and secondary forms, is associated with higher incidence and severity of coronary artery disease. | [
"http://www.ncbi.nlm.nih.gov/pubmed/23470525",
"http://www.ncbi.nlm.nih.gov/pubmed/22877896",
"http://www.ncbi.nlm.nih.gov/pubmed/22724581",
"http://www.ncbi.nlm.nih.gov/pubmed/21745107",
"http://www.ncbi.nlm.nih.gov/pubmed/19650571",
"http://www.ncbi.nlm.nih.gov/pubmed/19609889",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23470525",
"endSection": "abstract",
"offsetInBeginSection": 1516,
"offsetInEndSection": 1747,
"text": "The results showed that higher levels of TSH within the reference range were independently associated with the... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023921",
"http://www.nlm.nih.gov/cgi/mesh/2... | [] | 531d1279b166e2b806000042 | bioasq_yesno |
yesno | Is poly (ADP- ribosylation) involved in transcriptional control? | ['yes'] | [
"yes"
] | Yes, poly (ADP- ribosylation) plays a role in the maintenance of transcriptional fidelity. | [
"http://www.ncbi.nlm.nih.gov/pubmed/18851700",
"http://www.ncbi.nlm.nih.gov/pubmed/18396434",
"http://www.ncbi.nlm.nih.gov/pubmed/17286852",
"http://www.ncbi.nlm.nih.gov/pubmed/17158748",
"http://www.ncbi.nlm.nih.gov/pubmed/9790974",
"http://www.ncbi.nlm.nih.gov/pubmed/1828533"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18851700",
"endSection": "abstract",
"offsetInBeginSection": 336,
"offsetInEndSection": 547,
"text": "Histone phosphorylation, ubiquitylation, SUMOylation and poly-ADP-ribosylation, as well as ATP-dependent nucleos... | 5 | BioASQ-training5b | [
"http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070212",
"http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006351",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020727"
] | [] | 53380000d6d3ac6a34000059 | bioasq_yesno |
factoid | What is molecular radiotherapy? | ['Molecular radiotherapy is working through tumor-targeted radionuclides.'] | [
"Molecular radiotherapy",
"Tumor-targeted radionuclides",
"Targeted radionuclide therapy",
"Radionuclide therapy",
"Radioimmunotherapy",
"Radionuclide-based therapy",
"Targeted molecular therapy"
] | ['Molecular radiotherapy is working through tumor-targeted radionuclides.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/28747518",
"http://www.ncbi.nlm.nih.gov/pubmed/29043399"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28747518",
"endSection": "abstract",
"offsetInBeginSection": 311,
"offsetInEndSection": 405,
"text": "Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges"
},
{
"be... | 11 | BioASQ-training11b | null | null | 5e499c636d0a27794100000a | bioasq_factoid |
factoid | Which is the target of the drug Denosumab? | [['receptor activator of nuclear factor-κB ligand', 'RANKL']] | [
"receptor activator of nuclear factor-κB ligand",
"RANKL",
"RANK ligand",
"receptor activator of NF-kB ligand",
"TNFSF11",
"OPGL",
"osteoprotegerin ligand"
] | ['Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL).'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/26029270",
"http://www.ncbi.nlm.nih.gov/pubmed/26203221",
"http://www.ncbi.nlm.nih.gov/pubmed/26504466",
"http://www.ncbi.nlm.nih.gov/pubmed/26508890"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26029270",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 156,
"text": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor κB ligand ... | 5 | BioASQ-training5b | [] | [] | 56e6ec49edfc094c1f000005 | bioasq_factoid |
factoid | Which transcription factor binding site is contained in Alu repeats? | ['The NF-κB-binding site'] | [
"NF-kappa B binding site",
"NF-κB binding site",
"Nuclear factor kappa-light-chain-enhancer of activated B cells binding site",
"NF-kB binding site",
"NFκB-binding site",
"NF-kappaB binding site",
"The NF-κB-binding site"
] | ['A novel abundant NF-κB-binding site resides in specialized Alu-repetitive elements having the potential for long range transcription regulation, thus suggesting that in addition to its known role, NF-κB has a primate-specific function and a role in human evolution.', 'Remarkably, we identified a novel abundant NF-κB-... | [
"http://www.ncbi.nlm.nih.gov/pubmed/23771139",
"http://www.ncbi.nlm.nih.gov/pubmed/21896491"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21896491",
"endSection": "abstract",
"offsetInBeginSection": 502,
"offsetInEndSection": 794,
"text": "Remarkably, we identified a novel abundant NF-κB-binding site residing in specialized Alu-repetitive elements ha... | 11 | BioASQ-training11b | null | null | 5c74111f7c78d694710000a1 | bioasq_factoid |
factoid | The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger? | [['Na(+)/Ca(2+) exchanger', 'NCX']] | [
"Na(+)/Ca(2+) exchanger",
"NCX",
"sodium/calcium exchanger",
"sodium calcium exchanger",
"Na+/Ca2+ exchanger",
"Na+/Ca2+ antiporter",
"Na+/Ca2+ exchange protein"
] | ['SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), is a selective NCX inhibitor in vivo.', 'The effects of SEA0400, a selecti... | [
"http://www.ncbi.nlm.nih.gov/pubmed/23441899",
"http://www.ncbi.nlm.nih.gov/pubmed/22119380",
"http://www.ncbi.nlm.nih.gov/pubmed/22075452",
"http://www.ncbi.nlm.nih.gov/pubmed/21903118",
"http://www.ncbi.nlm.nih.gov/pubmed/21672583",
"http://www.ncbi.nlm.nih.gov/pubmed/20447431",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23441899",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 341,
"text": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation... | 5 | BioASQ-training5b | [] | [] | 5506c3e38e1671127b00000a | bioasq_factoid |
factoid | What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy? | ['8%'] | [
"8 percent",
"eight percent",
"0.08",
"0.08 fraction",
"8/100"
] | ['The global prevalence of intellectual developmental disorder (IDD) is 8% in Becker muscular dystrophy.', 'The global prevalence of intellectual developmental disorder (IDD) in Becker muscular dystrophy (BMD) is 8%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%.', 'The gl... | [
"http://www.ncbi.nlm.nih.gov/pubmed/36440509"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
"endSection": "abstract",
"offsetInBeginSection": 1369,
"offsetInEndSection": 1471,
"text": "The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy"
},
... | 13 | BioASQ-training13b | null | null | 66300d3e187cba990d00001b | bioasq_factoid |
factoid | Which deficiency is the cause of restless leg syndrome? | ['iron'] | [
"iron",
"ferrous",
"ferric",
"Fe",
"element 26",
"iron metal"
] | It has been well-documented that iron deficiency is the cause of restless leg syndrome. Magnesium and ferritin were also associated with restless leg syndrome. | [
"http://www.ncbi.nlm.nih.gov/pubmed/23940258",
"http://www.ncbi.nlm.nih.gov/pubmed/22486183",
"http://www.ncbi.nlm.nih.gov/pubmed/21358851",
"http://www.ncbi.nlm.nih.gov/pubmed/21211209",
"http://www.ncbi.nlm.nih.gov/pubmed/20814842",
"http://www.ncbi.nlm.nih.gov/pubmed/20598107",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23940258",
"endSection": "abstract",
"offsetInBeginSection": 438,
"offsetInEndSection": 775,
"text": "We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in th... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012148",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003677",
"http://www.disease-ontology.org/api/metadata/DOID:0050425"
] | [] | 530cefaaad0bf1360c000012 | bioasq_factoid |
factoid | What is the role of DNA Repair Cofactors ATMIN and NBS1? | ['Suppresion of T Cell Activation.'] | [
"Suppression of T Cell Activation",
"T Cell Activation Suppression",
"Inhibition of T Cell Activation",
"T Cell Suppression",
"T Cell Inhibition"
] | ['The DNA double-strand break signaling kinase ATM and its cofactor NBS1 are required during T cell development and for the maintenance of genomic stability. The role of a second ATM cofactor, ATMIN (also known as ASCIZ) in T cells is much less clear, and whether ATMIN and NBS1 function in synergy in T cells is unknown... | [
"http://www.ncbi.nlm.nih.gov/pubmed/26544571"
] | [
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 79,
"text": "DNA Repair Cofactors ATMIN and NBS1 Are Required to Suppress T Cell Activation."
},
{
"beginSection": "abstract",... | 6 | BioASQ-training6b | [
"http://www.uniprot.org/uniprot/NBS1_SCHPO",
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004260",
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045643",
"https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&t... | [
{
"o": "DNA repair",
"p": "http://www.w3.org/2000/01/rdf-schema#label",
"s": "http://linkedlifedata.com/resource/umls/id/C0012899"
},
{
"o": "http://linkedlifedata.com/resource/umls/label/A18609617",
"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
"s": "http://linkedlifedata.com/resou... | 58853c56e56acf5176000018 | bioasq_factoid |
factoid | Which company produces Eligard? | ['Astellas Pharma GmbH'] | [
"Astellas Pharma GmbH",
"Astellas Pharma",
"Astellas",
"Astellas Pharma Inc.",
"Astellas Pharma Limited"
] | ['Eligard is produced by Astellas Pharma GmbH.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/29197875"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29197875",
"endSection": "abstract",
"offsetInBeginSection": 14,
"offsetInEndSection": 242,
"text": "We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard... | 11 | BioASQ-training11b | null | null | 5e776443835f4e4777000008 | bioasq_factoid |
factoid | What is Apretude used for? | ['HIV-1 pre-exposure prophylaxis'] | [
"HIV-1 pre-exposure prophylaxis",
"PrEP",
"HIV pre-exposure prophylaxis",
"HIV pre-exposure prophylaxis medication",
"HIV prevention pill"
] | ['Cabotegravir extended-release (ER) injectable suspension (Apretude™) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP).'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/36255686"
] | [
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 96,
"text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis."
},
{
"beginSect... | 12 | BioASQ-training12b | null | null | 6440420857b1c7a315000050 | bioasq_factoid |
factoid | Where are the orexigenic peptides synthesized? | [['The orexigenic peptides are sythesized in the hypothalamus.']] | [
"orexigenic peptides",
"appetite-stimulating peptides",
"hunger-inducing peptides",
"hypothalamic peptides",
"peptides synthesized in the hypothalamus",
"orexigenic neuropeptides"
] | ['The orexigenic peptides are sythesized in the hypothalamus.'] | [
"http://www.ncbi.nlm.nih.gov/pubmed/25502749",
"http://www.ncbi.nlm.nih.gov/pubmed/25258168",
"http://www.ncbi.nlm.nih.gov/pubmed/25039297",
"http://www.ncbi.nlm.nih.gov/pubmed/24991043",
"http://www.ncbi.nlm.nih.gov/pubmed/25241055",
"http://www.ncbi.nlm.nih.gov/pubmed/25017744",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25502749",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 84,
"text": "Orexin A and B, orexigenic peptides produced primarily by the lateral hypothalamus t"
},
{
"beginSection": ... | 5 | BioASQ-training5b | [] | [] | 56e47e0051531f7e3300001c | bioasq_factoid |
yesno | Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients? | ['no'] | [
"no"
] | ['Spinal intradural primary malignant peripheral nerve sheath tumors (MPNST) are rare in patients without neurofibromatosis.', 'No, Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in patients without neurofibromatosis.', 'yes, Primary malignant peripheral nerve sheath tumors (MPNSTs) are ... | [
"http://www.ncbi.nlm.nih.gov/pubmed/27593814",
"http://www.ncbi.nlm.nih.gov/pubmed/24926928"
] | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27593814",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 122,
"text": "Spinal intradural primary malignant peripheral nerve sheath tumors (MPNST) are rare in patients without neurofibro... | 11 | BioASQ-training11b | null | null | 5e67bc121af46fc13000001c | bioasq_yesno |
yesno | Is JTV519 (K201) a potential drug for the prevention of arrhythmias? | ['yes'] | [
"yes"
] | Yes, JTV519 has antiarrhythmic properties. | [
"http://www.ncbi.nlm.nih.gov/pubmed/23144205",
"http://www.ncbi.nlm.nih.gov/pubmed/22563249",
"http://www.ncbi.nlm.nih.gov/pubmed/22001562",
"http://www.ncbi.nlm.nih.gov/pubmed/21291389",
"http://www.ncbi.nlm.nih.gov/pubmed/20581784",
"http://www.ncbi.nlm.nih.gov/pubmed/20080988",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205",
"endSection": "abstract",
"offsetInBeginSection": 330,
"offsetInEndSection": 636,
"text": "We compared the suppressive effect of K201 (JTV519), a multiple-channel blocker and cardiac ryanodine receptor-c... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000889"
] | [
{
"o": "C109183",
"p": "http://www.w3.org/2004/02/skos/core#notation",
"s": "http://linkedlifedata.com/resource/umls/label/A16995906"
},
{
"o": "JTV-519",
"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
"s": "http://linkedlifedata.com/resource/umls/label/A17004235"
},
{
"o"... | 52b2f1724003448f5500000b | bioasq_yesno |
yesno | Does the 3D structure of the genome remain stable during cell differentiation? | ['no'] | [
"no"
] | ['Many studies have suggested a link between the spatial organization of genomes and fundamental biological processes such as genome reprogramming, gene expression, and differentiation. The open chromatin of embryonic stem cells (ESCs) condenses into repressive heterochromatin as cells exit the pluripotent state. The r... | [
"http://www.ncbi.nlm.nih.gov/pubmed/22495300",
"http://www.ncbi.nlm.nih.gov/pubmed/26340639",
"http://www.ncbi.nlm.nih.gov/pubmed/25218583",
"http://www.ncbi.nlm.nih.gov/pubmed/24346698",
"http://www.ncbi.nlm.nih.gov/pubmed/24305663",
"http://www.ncbi.nlm.nih.gov/pubmed/25479748",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22495300",
"endSection": "abstract",
"offsetInBeginSection": 940,
"offsetInEndSection": 1109,
"text": "We identify large, megabase-sized local chromatin interaction domains, which we term 'topological domains', as ... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002454",
"http://amigo.geneontology.org/amigo/term/GO:0030154",
"http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"
] | [] | 56ebfac12ac5ed1459000001 | bioasq_yesno |
factoid | Inhibition of which transporter is the mechanism of action of drug Canagliflozin? | ['sodium glucose co-transporter 2'] | [
"sodium glucose co-transporter 2",
"SGLT2",
"Sodium-glucose transport protein 2",
"Sodium-glucose cotransporter 2",
"Sodium-glucose co-transporter type 2"
] | Inhibition of sodium glucose co-transporter 2 (SGLT2) is the major mechanism of action of canagliflozin. Canagliflozin is the first SGLT2 inhibitor to be approved in the USA for the treatment of type 2 diabetes and is under regulatory review in the EU. Other SGLT2 inhibitors include dapagliflozin and empagliflozin. | [
"http://www.ncbi.nlm.nih.gov/pubmed/22621689",
"http://www.ncbi.nlm.nih.gov/pubmed/22547464",
"http://www.ncbi.nlm.nih.gov/pubmed/21680987",
"http://www.ncbi.nlm.nih.gov/pubmed/24257692",
"http://www.ncbi.nlm.nih.gov/pubmed/24040872",
"http://www.ncbi.nlm.nih.gov/pubmed/24025022",
"http://www.ncbi.nlm.n... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24257692",
"endSection": "abstract",
"offsetInBeginSection": 303,
"offsetInEndSection": 436,
"text": "During the past year, two SGLT2 inhibitors, canagliflozin and dapagliflozin, have been approved for the treatmen... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002352",
"http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051051",
"http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0032410",
"http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+... | [] | 5335c7f2d6d3ac6a34000051 | bioasq_factoid |
yesno | Are immune cells affected in Amyotrophic Lateral Sclerosis? | ['yes'] | [
"yes"
] | ['In ALS T-cell deficiency increases neuronal loss, while boosting T cell levels reduces it.', 'Therapeutic immunization of mSOD1 mice with a myelin-derived peptide led to CP activation, and was followed by the accumulation of immunoregulatory cells, including IL-10-producing monocyte-derived macrophages and Foxp3(+) r... | [
"http://www.ncbi.nlm.nih.gov/pubmed/25904790",
"http://www.ncbi.nlm.nih.gov/pubmed/21829620",
"http://www.ncbi.nlm.nih.gov/pubmed/7551976",
"http://www.ncbi.nlm.nih.gov/pubmed/7595631",
"http://www.ncbi.nlm.nih.gov/pubmed/23881705",
"http://www.ncbi.nlm.nih.gov/pubmed/17852013",
"http://www.ncbi.nlm.nih... | [
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
"endSection": "abstract",
"offsetInBeginSection": 787,
"offsetInEndSection": 1125,
"text": "Therapeutic immunization of mSOD1 mice with a myelin-derived peptide led to CP activation, and was followed by ... | 5 | BioASQ-training5b | [
"http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477",
"http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000690",
"http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012598",
"http://www.disease-ontology.org/a... | [] | 56cae51f5795f9a73e000025 | bioasq_yesno |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 5